Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5902498 | Journal of Diabetes and its Complications | 2015 | 5 Pages |
Abstract
Treatment with paricalcitol at this dose and duration did not affect brachial artery FMD or biomarkers of inflammation and oxidative stress. The lack of significance may be due to the fact that the study patients had advanced CKD and that effects of paricalcitol are not additive to the effects of glycemic, lipid and anti-hypertensive therapies.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Tina K. Thethi, Muhammad A. Bajwa, Husam Ghanim, Chanhee Jo, Monica Weir, Allison B. Goldfine, Guillermo Umpierrez, Cyrus Desouza, Paresh Dandona, Ying Fang-Hollingsworth, Vasudevan Raghavan, Vivian A. Fonseca,